“Orion, C4 Imaging’s Positive Signal HDR MRI Marker, which is based on the encapsulation of C4, our unique MRI agent, allows accurate positive-signal MRI treatment planning to be offered to cancer patients suitable for HDR treatment. C4 Imaging is delighted to partner with Theragenics, a longtime leader in serving the brachytherapy marketplace. We believe they will be a vital partner in making this new technology available to radiation oncologists and to patients,” said Andrew Bright, president and CEO of C4 Imaging, in a press release.
The Orion marker is used prior to high dose rate (HDR) brachytherapy to locate the position of applications that are used to guide the placement of radioactive sources to treat multiple types of cancer. Using MRI imaging, applicators are able to be more accurately placed for a more accurate delivery of radiation to tumor sites while avoiding healthy tissue and cells.
“C4 Imaging’s innovative HDR MRI marker should benefit patients by allowing more precise delivery of HDR brachytherapy, maximizing the therapeutic benefits of this treatment while minimizing potential side effects. We will utilize our expertise in brachytherapy and our established sales organization to effectively introduce and support the Orion,” Frank Tarallo, president and CEO of Theragenics, said. “Theragenics has supported brachytherapy and the radiation oncology community for over 35 years. Leveraging our expertise and assets in our brachytherapy business, including our sales organization and our manufacturing capabilities in medical devices and nuclear medicine, is an important part of our strategy. We look forward to making this exciting new technology available to healthcare providers and patients.”